Channel Therapeutics Corporation (AMEX:CHRO) has seen 0.48 million shares traded in the recent trading session. The company, currently valued at $3.60M, closed the recent trade at $0.60 per share which meant it lost -$0.02 on the day or -3.54% during that session. The CHRO stock price is -900.0% off its 52-week high price of $6.00 and 25.0% above the 52-week low of $0.45. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.19 million shares traded. The 3-month trading volume is 163.97K shares.
The consensus among analysts is that Channel Therapeutics Corporation (CHRO) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Channel Therapeutics Corporation (AMEX:CHRO) trade information
Sporting -3.54% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CHRO stock price touched $0.60 or saw a rise of 15.49%. Year-to-date, Channel Therapeutics Corporation shares have moved -87.55%, while the 5-day performance has seen it change -8.08%. Over the past 30 days, the shares of Channel Therapeutics Corporation (AMEX:CHRO) have changed -5.14%. Short interest in the company has seen 58233.0 shares shorted with days to cover at 0.26.
CHRO Dividends
Channel Therapeutics Corporation is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
